A Study Of Recombinant Interferon Gamma (rIFN-γ) And Intravenous Immunoglobulin On Treating Viral Myocarditis

Objective:To explore the cell immunologic mechanism of viral myocarditis on BALB/C mice. To investigate the therapeutic effects of intravenous immunoglobulin(IVIG) and interferon gamma(rINF-γ) on viral myocarditis.Methods:BALB/C mice were divided into four groups random, normal group(A),virus group(B), induced rIFN-γ group(C) and IVIG group (D) .The virus titer were detected in the mice myocardium. The mice myocarditis were diagnosed with routine histopathological method. 164 patients with viral myocarditis were divided into four groups. 41 patients were given rINF-γ(3-7years half million U/d;≥7 years one million U/d) for two weeks(the first group).42 patients were given IVIG(400mg/kg.d) for five days(the second group).41 patients were given both rINF-γ and IVIG (the third group). The three groups were treated simultaneously with usual therapy. The other 40 patients were usual therapy only as a control group(the fourth group). We compared the changes of clinical expression, electrocardiogram(ECG) and cardiac troponin I (CTnI) and CK-MB.Results:The peak titer of BALB/C in A group mice myocarditis were higher than other groups. Clinical curative effect: The total effective rate of the treatment group was evident, while that of the control group was 49%. It was evident for difference between them (p<0.01). ECG total effective rate of the treatment group was 86.2%, and that of control group was 38.7%. It was statistically significant (p<0.01). CTnI and CK-MB in the four groups were evident difference(p<0.05).Conclusion:The cell immunology plays an important role in the pathogeneses of virus-induced myocarditis. There is evident curative effect and no side effect in using rINF-γ and IVIG to treat viral myocarditis .